Oppenheimer Reiterates Outperform on LeMaitre Vascular, Raises Price Target to $93
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Suraj Kalia has reiterated an Outperform rating for LeMaitre Vascular (NASDAQ:LMAT) and increased the price target from $90 to $93.
November 01, 2024 | 4:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has reiterated an Outperform rating for LeMaitre Vascular and increased the price target from $90 to $93, indicating positive analyst sentiment.
The reiteration of an Outperform rating and an increase in the price target by a reputable analyst can boost investor confidence and potentially lead to a short-term increase in LMAT's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100